Cargando…
A randomised trial of Mycobacterium w in critically ill patients with COVID-19: ARMY-1
PURPOSE: We investigated whether Mycobacterium w (Mw), an immunomodulator, would improve clinical outcomes in coronavirus disease 2019 (COVID-19). METHODS: We conducted an exploratory, randomised, double-blind, placebo-controlled trial of hospitalised subjects with severe COVID-19 (pulmonary infiltr...
Autores principales: | Sehgal, Inderpaul Singh, Guleria, Randeep, Singh, Sarman, Siddiqui, Mohammad Sabah, Agarwal, Ritesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942222/ https://www.ncbi.nlm.nih.gov/pubmed/34031642 http://dx.doi.org/10.1183/23120541.00059-2021 |
Ejemplares similares
-
Safety of an immunomodulator Mycobacterium w in COVID-19
por: Sehgal, Inderpaul Singh, et al.
Publicado: (2020) -
Sleep after critical illness: Study of survivors of acute respiratory distress syndrome and systematic review of literature
por: Dhooria, Sahajal, et al.
Publicado: (2016) -
Pulse methylprednisolone in allergic bronchopulmonary aspergillosis exacerbations
por: Singh Sehgal, Inderpaul, et al.
Publicado: (2014) -
Diagnosis of Chronic Pulmonary Aspergillosis: Which Is the Best Investigation?
por: Sehgal, Inderpaul Singh, et al.
Publicado: (2023) -
Fungal bronchitis or allergic bronchopulmonary aspergillosis …that is the question
por: Sehgal, Inderpaul Singh, et al.
Publicado: (2021)